UNSPSC 51361929: Aprobarbital sodium

This classification denotes a barbiturate C10H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T90V76R18, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2- propenyl)-, monosodium salt, but more generally known as aprobarbital sodium, which bears US NIH Compound Identifier 23662380. Most nations, for tariff and trade purposes, schedule aprobarbital sodium under HS 29335400 and SITC kg. As of Q4 2014, APROBARBITAL SODIUM remains US FDA's Preferred Term for this commodity.

SMILES: CC(C)C1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].

UNSPSC 51361929 Aprobarbital sodium is a Commodity code that nominally covers a specific barbiturate pharmaceutical product, but recent state and local solicitations tagged with this code reflect a much broader scope: acquisition of pharmaceutical products and medical supply systems for public health initiatives, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local buyers under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The purchasing bodies treat this code as an umbrella for controlled-substance management supplies, harm-reduction products, and generic pharmaceutical procurement rather than aprobarbital sodium specifically, suggesting the code may function as a placeholder or aggregated category within state and local taxonomy systems. Work solicited includes direct product procurement with quarterly or as-needed delivery schedules, compliance with cGMP and Drug Supply Chain Security Act standards, and integration with existing wholesale distribution networks.

Recent activity appears across Florida, Texas, and Minnesota, with the most visible opportunities in cooperative purchasing vehicles and state agency programs. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to its Community Health Building, with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory solicitation designed to inform future formal procurement specifications. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026 and effective contract date July 1, 2026. These three opportunities illustrate the code's current use for multi-jurisdiction cooperative contracts, direct-to-agency pharmaceutical supply, and harm-reduction product procurement rather than specialty-drug procurement.